Patent · US Active

Epstein-Barr-virus vaccine

US10300129B2 · kind B2 · utility

2Cited by

0References

9Claims

0Family size

Assignee

Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) · DE

Inventors

Romana Ruiss · Munich, DE
Gilbert Reisbach · Hersbruck, DE
Wolfgang Hammerschmidt · Munich, DE
Reinhard Zeidler · Birkenfeld, DE

Key dates

Filing date	Mar 22, 2016
Grant date	May 28, 2019
Priority date	—
Expiry date	Jun 11, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2710/16271
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a vaccine comprising a particle, said particle comprising (i) at least one Epstein-Barr virus (EBV) structural polypeptide, (ii) at least one EBV lytic polypeptide, (iii) membrane lipids, said particle being devoid of EBV DNA, wherein (a) the B-cell transformation capacity of one or more EBV polypeptides required for B-cell transformation as comprised in said particle is disabled while their immunogenicity is maintained; and or (b) said particle is devoid of one or more EBV polypeptides required for B-cell transformation. Furthermore, the invention relates to a method for generating a particle, to a cell obtained in the method of the invention, a kit comprising the vaccine or the particle generated according in the method of the invention. Also, the invention relates to the use of the vaccine or the particle generated according to the method of the invention for generating CD8+ cells specific for an EBV antigen.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.